ALEXANDRIA, Va.– Biologics Consulting Group, Inc. is pleased to announce the appointment of Dr. Margaret K. Vernon as Chief Executive Officer, effective September 18, 2023. Dr. Vernon joins Biologics Consulting Group after 17 years with Evidera, a business unit of PPD.
Margaret served as senior vice president and general manager for the Evidera Advisory Business Unit within the PPD clinical research business of Thermo Fisher Scientific. In this role, she had global executive leadership and P&L responsibilities for Evidera’s combined consulting practices (data and analytics, evidence synthesis, modeling and communication, development, and value/access consulting, as well as patient-centered research, medical writing, and health care communications). She also supported the overall patient-centricity strategy for the PPD business.
Margaret earned her Ph.D. in Developmental Psychology with a concentration in statistics and research methodology from The Pennsylvania State University, State College, PA, and additional training in finance and accounting from the Wharton Executive Program.
“We are delighted to welcome Margaret to the Biologics Consulting management team,” stated Dr. Norman W. Baylor, former President, and CEO of Biologics Consulting. “Margaret is dynamic, creative, and results driven. She has a strong leadership background and a clear strategic vision for the firm. Margaret is sure to serve as an excellent leader for the Biologics Consulting team as they help clients to advance the future of vaccines, biologics, drugs, and medical devices.” Dr. Vernon will succeed Dr. Baylor, who will remain as Chair of the Biologics Consulting Board of Directors.
Dr. Vernon is a highly accomplished leader and an expert regarding patient-reported outcome (PRO) instrument development and validation programs with a special interest in measurement in rare diseases. She has expertise in regulatory strategy and PRO clinical trial implementation and analysis, as well as considerable experience and formal training in both qualitative and quantitative methods.
“It is a pleasure to have been chosen as Biologics Consulting’s new CEO,” said Dr. Vernon. “The company has built an impressive reputation of success, bolstered by an exceptional team of consultants, a diverse project portfolio, and an expansive global footprint. I very much look forward to leading the Biologics Consulting team as we use innovative approaches and multidisciplinary expertise to guide our clients through complex regulatory, scientific, and business challenges.”
Dr. Vernon was selected after an extensive national search conducted by the Biologic Consulting Board of Directors with the professional recruitment services of Odgers Berndtson.
